Study record
Nandrolone: telomere elongation and clinical improvement in telomeropathy (Clé et al., 2019)
Human clinical trial — disease population (conference abstract)
Two caveats govern every page on this site. (1) Telomere length is a contested aging biomarker — it is measured differently by different methods, varies between tissues, and "longer" is not straightforwardly "healthier"; changing a telomere-length or telomerase-activity number in a trial is not the same as slowing human aging. (2) Activating telomerase is not risk-free — telomerase is silenced in most somatic cells and reactivated in most cancers, so its activation raises an unresolved cancer-risk question. Tellingly, the only FDA-approved telomerase drug — imetelstat (RYTELO, 2024) — inhibits telomerase to treat cancer (lower-risk MDS), the opposite direction from the anti-aging "activation" narrative.
○ Evidence tier 2 — Human clinical-outcome RCT — disease population
Record
| Design | Prospective clinical trial of nandrolone in telomeropathies (ASH 2019 abstract) |
| DOI | 10.1182/blood-2019-130844 |
| Citation status | doi verified via Crossref 2026-07-12 (Blood 2019;134(Supplement_1):2501, Clé DV, Catto LF, ..., Calado RT, 'Telomere Elongation and Clinical Improvement in Telomeropathy Patients: A Prospective Clinical Trial of Nandrolone in Telomeropathies'). NOTE: this is an ASH annual-meeting abstract (Blood supplement), not a full peer-reviewed paper — no full paper published — the ASH/Blood abstract is the primary record. |
Five-qualifier claim
| Species / population | Patients with telomeropathies (inherited telomere-biology disorders) — a rare DISEASE population. |
| Exposure, route, schedule | Nandrolone (an anabolic androgen) in a prospective clinical trial in telomeropathies. |
| Comparator / duration | Prospective clinical trial (single-arm) with telomere-length and clinical endpoints. |
| Endpoint / numeric result | Reported telomere elongation and clinical improvement in treated telomeropathy patients — consistent with androgen upregulation of telomerase. |
| What it did NOT establish | A rare-disease result (and reported as a conference abstract, not a full journal paper). It is not healthy aging and not a lifespan outcome; androgen toxicity applies. |
Interventions
Primary reference
https://doi.org/10.1182/blood-2019-130844
Exact identifier confirmed against the primary record via Crossref/ClinicalTrials.gov where stated in the citation status; anything marked needs_primary_fulltext is not yet confirmed.